Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

Journal of Mammary Gland Biology and Neoplasia

Issue 2/2002

Content (10 Articles)

Preface

Preface

Jeffrey W. Pollard, Joyce Taylor-Papadimitriou

Defense of the Bovine Mammary Gland by Polymorphonuclear Neutrophil Leukocytes

Max Paape, Jalil Mehrzad, Xin Zhao, Johann Detilleux, Christian Burvenich

Engineering Immunity in the Mammary Gland

Andreas F. Kolb

Mammary Gland Immunity and Mastitis Susceptibility

Lorraine M. Sordillo, Katie L. Streicher

The Macrophage Growth Factor CSF-1 in Mammary Gland Development and Tumor Progression

Elaine Y. Lin, Valerie Gouon-Evans, Andrew V. Nguyen, Jeffrey W. Pollard

Do Inflammatory Cells Participate in Mammary Gland Involution?

Jenifer Monks, F. Jon Geske, Lisa Lehman, Valerie A. Fadok

Tumor-Associated Macrophages in Breast Cancer

Russell D. Leek, Adrian L. Harris

Influence of Breast Cancer on Thymic Function in Mice

Diana M. Lopez, Vijaya Charyulu, Becky Adkins

T Cell Memory, Anergy and Immunotherapy in Breast Cancer

Volker Schirrmacher, Markus Feuerer, Philipp Beckhove, Thorsten Ahlert, Viktor Umansky

MUC1 and the Immunobiology of Cancer

Joyce Taylor-Papadimitriou, Joy M. Burchell, Timothy Plunkett, Rosalind Graham, Isabel Correa, David Miles, Michael Smith

Jan 02
Issue: 1/2002
Jul 02
Issue: 3/2002

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits